Attending ISPOR EU 2023, Denmark? ——- Catch up with us at our exhibition or just drop by to pick up some Kindness goodies. See you ❤
Health Economic Modelling
Cutting-edge methods to ensure scientifically robust and user-friendly models
RWE & Data Analytics
Analysis of Real World Data to study disease epidemiology and its impact in each phase of product lifecycle
Review & Evidence Synthesis
Assessment of different studies within the scope of existing knowledge for a specific objective
Market access and Value communication
Effectively communicating the clinical and economic value of healthcare technologies to payers and reimbursement agencies
In a small group or personalized one on one session learn HEOR concepts from basic to advanced from the best in industry experts
We understand your Needs
This is why we focus on maintaining a perfect balance across the three dimensions of academic and professional efficiency.
Timeliness, Quality assurance and Value for money.
Introductory blog on the importance of community health workers in achieving universal health coverage and strengthening global health. This blog is based on author’s personal experience.
The innovation of the new treatments has outpaced the rate at which NICE (The National Institute for Health and Care Excellence) appraises the treatments via its existing method of appraisal. NICE recently announcing taking a “proportionate approach” to technology appraisals is a landscape change ensuring faster guidance and efficiency gains.
Framework of Developing Real world Evidence (RWE) There has been a burgeoning bid about the use of Real-World data in healthcare. The National Institute for Health and Care Excellence (NICE) has released the NICE real-world evidence framework on 23rd June 2022 which...
Cost-Effectiveness of Lenvatinib Compared with Sorafenib for the First-Line Treatment of Advanced Hepatocellular Carcinoma in Australia
Saiyed M, Byrnes J, Srivastava T, Scuffham P, Downes M
In the REFLECT trial, lenvatinib showed superior clinical benefits to sorafenib in terms of progression-free survival and was non-inferior for overall survival in the treatment of advanced hepatocellular carcinoma (HCC). The study assessed the cost-effectiveness of lenvatinib compared with sorafenib for patients with advanced HCC in Australia.
Improving Cycle Corrections in Discrete Time Markov Models: A Gaussian Quadrature Approach [Pre Print]
Srivastava T, Strong M, Stevenson MD, Dodd P
In this study, a novel cycle correction method based on Gaussian Quadrature (GQ) is introduced for Markov Models. A simulation study was conducted to compare the GQ method with existing methods. Fifth order GQ method outperformed other existing methods in 99.8% scenarios.
Volume–Outcome Relationships in Open and Endovascular Repair of Abdominal Aortic Aneurysm: Administrative Data 2006–2018
Tong T, Aber A, Chilcott J, Thokala P et al
The aim of this study was to analyse real-world hospital-based patient level data (70k+ patients) to investigate and update volume–outcome relationships after open surgical repair (OSR) and endovascular repair (EVAR) of abdominal aortic aneurysm in England.